Trial
NCT05270265
Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine
Early Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Oxford
Collaborators
—
Condition
Malaria, Vivax
Intervention
Pvs25-IMX313/Matrix-M1
Why stopped
The study was terminated due to administrative delays in the approval of a substantial amendment to extend the shelf-life of Pvs25-IMX313. Regulatory approval was only received on 11 August 2023, after end of study visits had already been conducted.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-15